Fresh out of stealth mode, the startup medicine software developer Deep Lens Inc. has managed to raise $14 million as of today according to VentureBeat. With fresh capital in hand, the company hopes to not only expand its platform in terms of services but also leverage their success in the pathology market. How they hope to do this is to “Apply a highly disruptive approach to patient identification in clinical trials,” says Deep Lens President and co-founder Simon Arkell which he claims is a time-consuming issue for the pharmaceutical world in general.
Because clinical trials typically consist of hundreds and even thousands of participants, it’s not always easy keeping track of them even in the age of the Internet. Deep Lens’ solution to this is an AI tool called Virtual Imaging for Pathology Education and Research (or VIPER). However, Deep Lens isn’t the only company that’s developing electronic tools for health care purposes. For instance, there is PathAI which seeks to evolve pathology using machine learning for more accurate diagnoses. What makes Deep Lens different, though, is that it isn’t just planning to offer its services to hospitals and various clinics but also pharmaceutical companies who are very interested in VIPER’s capabilities.
About Virtual Imaging for Pathology Education and Research
Abbreviated as VIPER, it comes with a variety of assets including APIs that make collaboration between peers easier. In terms of its use in clinical trials, VIPER “Can flag eligible patients at the time of their diagnosis,” VentureBeat states which allows for a quicker enrollment rate.
About Deep Lens Inc.
Based in Columbus, Ohio, it was founded by Dave Billiter, who is its current CEO, Simon Arkell and TJ Bowen, a former Cardinal Health director. An Ohio native, Billiter graduated from Ohio Northern University as well as Columbus Southern University. Then after Billiter became part of the Nationwide Children’s Hospital in 2004, an oncology studies suite driven by AI was created with Billiter overseeing its creation. Since then, various clinicians at 65 institutions from eight countries across the world have used this suite. The investors responsible for the company’s funding include Northpond Ventures, Rev1 Ventures, Sierra Ventures, along with Tamarind-Hill Partners.